Surrey Heartlands

Joint Formulary & PAD

Budesonide with formoterol (DuoResp Spiromax) - Chronic Obstructive Pulmonary Disease (COPD)

You are here : Home > Formulary Search > Budesonide with formoterol (DuoResp Spiromax) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Inhaler (dry powder)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important

DuoResp Spiromax 160/4.5 - second line (Fobumix Easyhaler (budesonide/formoterol) is the more cost-effective option DPI).

Prescribe by BRAND.

 

Status 2

Non Formulary
Formulations :
  • Inhaler (dry powder)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NFD1
Restrictions / Comments :
Important

DuoResp Spiromax 320/9 - this strength is not recommended in the Surrey Heartlands COPD guidelines.

Documentation

Guidelines (Local)
In-Check device for improving inhaler technique - Nov 16
Guidelines (Local)
COPD Primary Care Medicines Management Guidelines - updated Jun 23
Webpage
How to use a Spiromax inhaler - Patient information leaflet
Webpage
How to use a Spiromax inhaler - video

PAD Profile

ChemicalSubstance :
Budesonide with formoterol (DuoResp Spiromax)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
ICS LABA
Keywords :
ICS/LABA
Brand Names Include :
DuoResp Spiromax
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Chronic Obstructive Pulmonary Disease (COPD)
Supporting Documents :
4
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Budesonide with formoterol (DuoResp Spiromax) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

04 Mar 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Duoresp Spiromax (budesonide / formoterol DPI) is NOT a locally preferred device although there is no expectation for existing stable patients to change drug or device unless agreed as a clinically appropriate course of action.

The locally preferred ICS/LABA devices are as follows:

Low carbon:

  • Fostair Nexthaler (beclometasone / formoterol DPI)
  • Fobumix Easyhaler (budesonide / formoterol DPI)
  • Relvar Ellipta (Fluticasone / vilanterol DPI)
  • Symbicort Turbohaler (budesonide / formoterol DPI)

Alternative devices:

  • Fostair (beclometasone / formoterol MDI)
  • Symbicort (budesonide / formoterol MDI)

Devices should be prescribed by BRAND

A spacer device should be used with MDI devices.

See full COPD guidelines below